Tirzepatide for weight loss

GLP-1 and GIP are both incretin hormones — gut signals released around eating. Semaglutide engages one of those pathways. Tirzepatide engages both, which is a genuine structural difference rather than a marketing distinction.

What research explores is whether engaging both changes outcomes relative to engaging one. That is an active area, and how it applies to any individual is a matter for a clinician reviewing that person's history.

Tirzepatide is injection-only. There is no oral form, which is a real point of difference against semaglutide.

Zepbound also carries a licensed use relating to obstructive sleep apnea in adults with obesity. If that applies to you it is well worth raising, because it can change the coverage conversation entirely.

Compounded copies of these medicines were widely available while the branded products were in shortage, under federal allowances tied specifically to shortage status. The FDA has since declared both shortages resolved, which narrowed that permission substantially. A compounded version is not a generic and has not been through the approval process the branded product went through.

The tirzepatide shortage was declared resolved before the semaglutide one, so programmes offering compounded tirzepatide have been operating under a narrowed permission for longer. Ask directly what authority they are compounding under.

Tirzepatide carries separate brands for separate licensed indications, and which one a prescription is written against is not a formality. It determines the label, and it very often determines whether anything is covered.

Plans commonly exclude weight-management indications as a category while covering the identical molecule prescribed for type 2 diabetes or for cardiovascular risk reduction. This is why two people can be prescribed tirzepatide and receive opposite coverage answers, and it is not something a clinic can talk a plan out of. The prescription has to reflect your actual clinical situation.

Under current Medicare policy, anti-obesity medications are coverable under Part D only when used for another medically accepted indication rather than for weight loss itself. CMS has proposed reinterpreting that exclusion and has separately launched a time-limited access route for Part D enrollees. Both are live, so confirm rather than assume.

If you are being prescribed for weight management and paying cash, ask whether an in-network prescriber could write against a different documented indication that genuinely applies to you. Sometimes the answer is no, and it is worth asking rather than discovering later.

Tirzepatide is started low and adjusted upward in stages under supervision. That schedule is not a formality — it exists specifically to manage the gastrointestinal effects that are the most common reason people stop early, and moving through it faster than directed tends to defeat the purpose.

It is a weekly subcutaneous injection given with a device designed for self-administration, so most people manage it at home after being shown how. Storage requirements are real and worth asking about, particularly if you travel.

There are contraindications that exclude some people entirely, including specific personal and family medical histories that a prescriber will ask about directly. Bring that history rather than trying to work out in advance whether it disqualifies you, and read the manufacturer's medication guide for whichever product you are prescribed.

Expect it to be discussed as a long-term intervention rather than a short course, and expect the conversation to include what happens if you stop. That is a question worth raising early rather than a year in.

Start by finding out whether Zepbound is covered under your plan and what the prior-authorisation criteria are. Weight management is one of the most commonly excluded categories in US drug coverage, so this question comes before everything else.

If it is excluded, ask specifically whether the sleep apnea indication changes the assessment, and whether your record already documents anything relevant. That route is frequently overlooked and can alter the answer entirely.

Dosing is determined by a licensed provider.

How we verify providers

• CMS — Contract Year 2026 Policy and Technical Changes to the Medicare Advantage and Part D Programs (CMS-4208-P) fact sheet — retrieved 2026-08-06
• CMS — CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications — retrieved 2026-08-06
• FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — retrieved 2026-08-06